Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.
iSpecimen Inc., headquartered in Lexington, MA, is a leading marketplace for human biospecimens. The company provides researchers with the specimens they need from the patients they want through its innovative iSpecimen Marketplace. This online platform connects healthcare organizations with access to patients and specimens with scientists in need of these vital resources.
Utilizing proprietary, cloud-based technology, iSpecimen enables researchers to intuitively search for specimens across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. This system allows for easy and compliant access to specimens, facilitating scientific discovery and advancing healthcare for all.
iSpecimen stands out by offering a unique value proposition to both researchers and partner sites. Researchers gain the necessary resources to drive their studies, while partner sites can contribute to biomedical discovery and benefit financially. The company caters to a global market, with operations spanning the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority of its revenue coming from the Americas.
In recent news, iSpecimen has achieved a sequential quarterly revenue growth of 75%, driven by enhanced operational efficiencies and new business initiatives. The company continues to expand its network by adding new suppliers and reinforcing existing relationships to provide researchers with increased access to highly sought-after biospecimens, especially for oncology research. Additionally, iSpecimen is making strides in quality control and assurance through digital AI histopathology services, enhancing data quality and operational efficiency.
For investors and media inquiries, iSpecimen's contacts at KCSA Strategic Communications are available for further information.
iSpecimen Inc. (Nasdaq: ISPC) has expanded its Marketplace by adding seven new biospecimen sample providers in the U.S. and Europe. This strategic growth will enhance access to vital biospecimens for research in oncology, autoimmune and cardiovascular diseases. The new providers include a network for rapid blood collection and clinical trial groups contributing diverse biofluid specimens.
These additions allow researchers to reach larger patient populations with varied phenotypes. iSpecimen's ongoing commitment to improving supplier criteria is expected to bolster growth throughout 2023, enabling essential medical research.
iSpecimen Appoints Eric Langlois as Chief Revenue Officer
iSpecimen (Nasdaq: ISPC) has appointed Eric Langlois as Chief Revenue Officer, effective immediately. Langlois, previously Senior Vice President of Sales and Business Development, has played a pivotal role in achieving a remarkable 3,000% revenue growth during his tenure. He will manage a restructured commercial team to enhance alignment with customer needs and drive profitable growth. Under Langlois's leadership, iSpecimen has closed significant multi-million-dollar deals, contributing to record growth in Q4 2022. Langlois has extensive experience in pre-clinical research and biobanking, positioning him well to lead the company forward.
iSpecimen (Nasdaq: ISPC) has announced that CEO Tracy Curley will participate in the virtual Sequire Biotechnology Conference on February 2, 2023, at 5:00 p.m. ET. The company operates as an online marketplace connecting scientists with healthcare specimen providers for medical research. Interested attendees can register for the conference. iSpecimen utilizes proprietary cloud technology to facilitate searching for human biospecimens across a network of hospitals and labs. For more information about the conference or to arrange a meeting with management, attendees can reach out via email.
iSpecimen (Nasdaq: ISPC) announced that CEO Tracy Curley will participate in the Healthcare IT Virtual Conference, hosted by Maxim Group and M-Vest on January 25, 2023, at 8:30 a.m. ET. This conference aims to connect scientists with healthcare specimen providers for medical research. Attendees can register here. iSpecimen provides an online marketplace for biospecimens, facilitating research by connecting scientists with diverse healthcare providers.
iSpecimen Inc. (Nasdaq: ISPC) has appointed Tracy Curley as CEO, effective immediately, transitioning from her role as Interim CEO since September 2022. Curley expressed gratitude for the Board's confidence and highlighted the company's record revenue in Q4 2022. Andrew Ross, Chairman of the Board, commended Curley’s leadership and endorsed her permanent position. Following her appointment, a search for a new CFO will begin. iSpecimen connects scientists to biospecimens via an online marketplace, enhancing operational efficiency in medical research.
iSpecimen Inc. (Nasdaq: ISPC) has appointed Joseph J. Basile to its Board of Directors effective November 28, 2022, replacing Margaret H. Lawrence. Mr. Basile is a strategic advisor with extensive expertise in mergers, acquisitions, and corporate governance. His experience spans various sectors including life sciences and technology. Tracy Curley, Interim CEO, highlighted Mr. Basile's role in enhancing iSpecimen's M&A strategy. The company aims to leverage his skills to optimize stakeholder outcomes as it navigates significant operational transitions.
iSpecimen Inc. (Nasdaq: ISPC) reported Q3 2022 revenue of $2.6 million, with a record 88% ($2.26 million) from non-COVID sources, marking a 26% increase year-over-year. The company noted increased general and administrative expenses of about $2.2 million, resulting in a net loss of $3.1 million, compared to a $1.6 million loss in Q3 2021. Unique supplier and customer organizations increased to 217 and 480, respectively. iSpecimen’s cash reserves stood at approximately $20.7 million as of September 30, 2022. The company is pursuing multimillion-dollar initiatives and enhancing its Marketplace platform.
iSpecimen (Nasdaq: ISPC) has launched a new Open Feasibilities Dashboard on its iSpecimen Marketplace®, enhancing transparency for supplier partners in the biospecimen procurement process. This feature allows suppliers to easily review potential research projects and flag high-priority specimens for quicker assessments. The dashboard aims to address existing limitations in the biospecimen sourcing process, ultimately facilitating more efficient collaboration between researchers and healthcare providers. This update supports the company's mission to advance medical research.
iSpecimen (Nasdaq: ISPC), an online marketplace connecting scientists with healthcare specimen providers, will announce its third quarter financial results for the period ending September 30, 2022, before market open on November 8, 2022. An audio webcast and conference call will be held on the same day at 8:30 a.m. Eastern Time, featuring remarks from Tracy Curley, Interim CEO and CFO. A replay will be available until November 22, 2022.
For more information, visit www.ispecimen.com.
iSpecimen (Nasdaq: ISPC) has launched its Marketplace Onsite program to enhance support for biospecimen provider partners. By embedding coordinators at select partner sites, the program streamlines the fulfillment of sample and data requests, thereby reducing strain on staff. The initiative aims to expand the provider network, increase access to high-demand biospecimens, and improve revenue growth. Interim CEO Tracy Curley emphasized the program's potential to address supplier constraints and facilitate vital medical research.
FAQ
What is the current stock price of Ispecimen (ISPC)?
What is the market cap of Ispecimen (ISPC)?
What is iSpecimen Inc.?
Where is iSpecimen Inc. headquartered?
How does the iSpecimen Marketplace work?
What kind of specimens does iSpecimen provide?
What recent achievements has iSpecimen made?
Who can benefit from using iSpecimen's services?
What regions does iSpecimen operate in?
How can researchers access iSpecimen's services?
How does iSpecimen ensure quality control?
How can investors get in touch with iSpecimen?
